StockData
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd (TLX) stock

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30
$8.86−0.06 (-0.73%)

Close on Nov 17, 2026Market cap $3.00BP/E –Yield –

Telix Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Telix Pharmaceuticals's price to sales ratio was 4.1× on Nov 11, 2026, against 6.6× a year earlier. Over the last 2 years it ranged from 3.8× to 18.1×, with a median of 6.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.1×−0.9
2025Dec 31, 20255.0×−10.0
2024Dec 31, 202415.0×–

More Telix Pharmaceuticals figures

See a number that looks wrong?